R. Corrocher
University of Palermo
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by R. Corrocher.
Clinical & Experimental Allergy | 2001
Ml. Pacor; G. Di Lorenzo; R. Corrocher
Background The cause and pathogenesis of chronic urticaria are still poorly understood. IgE‐independent reactions, are common in adult patients with chronic urticaria, who have daily spontaneous occurrence of weals. H1‐receptor antagonists (antihistamines) are the major class of therapeutic agents used in the management of urticaria and angioedema. Nevertheless, chronic urticaria is often difficult to treat and may not be controlled by antihistamines alone. It has been postulated that mediators other than histamine, such as kinins, prostaglandin and leukotrienes, may be responsible for some of the symptoms in urticaria which are not controlled by antihistamines. In this study, which was randomized double‐blind, placebo‐controlled, we compare the clinical efficacy and safety of montelukast (MT) 10u2003mg given once a day and cetirizine (CET) 10u2003mg given once a day with placebo (PLA), in the treatment of patients with chronic urticaria who have positive challenge to acetylsalicylic acid (ASA) and/or food additives.
International Archives of Allergy and Immunology | 2005
Gabriele Di Lorenzo; Maria Luisa Pacor; Pasquale Mansueto; Nicola Martinelli; Maria Esposito-Pellitteri; Claudia Lo Bianco; Vito Ditta; Maria Stefania Leto-Barone; Nicola Napoli; Gaetana Di Fede; GiovamBattista Rini; R. Corrocher
Background: Recurrent chronic idiopathic urticaria (RCIU) is a common skin condition that affects 0.1–3% of the population in the USA and Europe and accounts for nearly 75% of all ‘ordinary’ chronic urticaria (CU) cases. Methods: We studied 838 consecutive patients with RCIU referred to hospital between 1998 and 2003. Patients with known causes of CU were excluded. Clinical history, physical examination, and symptom diaries were evaluated during two periods, a diet-free period (1 week) and a food-additive-free diet (FAFD) period (4 weeks), respectively, and two double-blind placebo-controlled (DBPC) challenges of six food additives were administered. The first DBPC challenge included a mixture of the six food additives (DBPCmixed) given to all patients. The second DBPC challenge comprised the single food additives, administered at increasing doses (DBPCsingle) to patients with a positive DBPCmixed test and 105 patients with a negative DBPCmixed test, as a control. Results: The DBPCmixed challenge was positive in 116 patients. None of the 105 control patients had a positive DBPCsingle test. Only 31 DBPCsingle tests were positive in patients with positive DBPCmixed challenge. Twenty-four of the 116 patients showing a positive DBPCmixed challenge also had a positive DBPCsingle result. Conclusions: Our results confirmed that food additive hypersensitivity reactions occurred in few RCIU patients using DBPCsingle challenge. The combination of the results of FAFD and DBPCmixed challenge seems to be of considerable practical interest for allergists, internists and dermatologists, rather than the data of clinical history and the results of DBPCsingle challenge, in patients with RCIU.
Clinical & Experimental Allergy | 2004
Ml. Pacor; G. Di Lorenzo; Nicola Martinelli; Pasquale Mansueto; Rini Gb; R. Corrocher
Background Atopic dermatitis (AD) is a chronic allergic inflammatory disease, which manifests itself with eczematous skin lesions.
Allergy | 2002
G. Di Lorenzo; Ml. Pacor; Antonio M. Vignola; M. Profita; Maria Esposito-Pellitteri; Domenico Biasi; R. Corrocher; Calogero Caruso
Background: The recovery of mediator metabolites from urine has the potential to provide a rapid, safe, and easily available index of release of mediators. We aimed to determine urinary metabolites of both histamine and leukotrienes (LTs) in patients affected by chronic urticaria (CU).
Allergy | 2004
Ml. Pacor; G. Di Lorenzo; Nicola Martinelli; Pasquale Mansueto; Rini Gb; R. Corrocher
Background:u2002 Very few data are available from the literature on whether nonatopic subjects affected by persistent rhinitis may show the appearance of objective symptoms of rhinitis after the ingestion of food additives such as tartrazine (E102), erythrosine (E127), monosodium benzoate (E211), p‐hydroxybenzoate (E218), sodium metabisulphite (E223), and monosodium glutamate (E620). It is still unclear whether the ingestion of food additive may cause, as well, a consensual reduction of nasal peak inspiratory flow (NPIFR). Therefore, we used a double‐blind placebo‐controlled (DBPC) study to evaluate this hypothesis.
International Archives of Allergy and Immunology | 2003
Ml. Pacor; G. Di Lorenzo; Nicola Martinelli; Giorgio Lombardo; A. Di Gregoli; Pasquale Mansueto; Rini Gb; Giovanni Corrocher; R. Corrocher
Background: The aetiology of recurrent aphthous stomatitis (RAS) has so far not been completely clarified. Recently, several studies reported that patients affected by cutaneous diseases (i.e. dermatitis, eczema and urticaria) with positive patch test to nickel have a positive oral nickel challenge. Objective: A retrospective data analysis of patch test and oral nickel challenge in 380 patients (204 women and 176 men) affected by RAS was performed. Patients and Methods: We examined 380 consecutive patients affected by RAS during the period 1990–1999. In 28/380 patients the appearance of their oral symptoms coincided with the fitting of orthodontic appliance, while 352/380 reported that their oral symptoms worsened after the fitting of orthodontic appliance. All patients were studied with the series (European standard series and series for dental materials) for patch tests. Results: Seventy out of 380 patients (18.4%) presented a contact sensitization to nickel sulphate (positive patch test). In all of these, the orthodontic appliance was replaced with one made of nickel-free materials. All patients were re-examined by the dentist 6 months after the removal of the orthodontic appliance. The symptoms had completely remitted in 28/70 patients, partially had improved in 31/70 patients and had remained unchanged in 11/70 patients. In all patients (n = 70) with a positive patch test to nickel we performed an oral double-blind placebo-controlled challenge (DBPC) test with nickel sulphate. The DBPC was positive in 32/70 patients, 21 of whom had partially improved and 11 had not, even after the replacement of the orthodontic appliance with material not containing nickel. None of the 28 patients in complete remission showed an adverse reaction to oral nickel challenge. Conclusion: The results of this study demonstrate that, in some patients with a positive patch test to nickel sulphate, the perpetuation of RAS can be related to a hypersensitivity to ingested nickel salts, independently of local contact to nickel.
Allergy | 2008
Giovanni Corrocher; G. Di Lorenzo; Nicola Martinelli; R. Corrocher; P. Votzakis; Ml. Pacor
Allergy | 2008
Giovanni Corrocher; G. Di Lorenzo; Nicola Martinelli; R. Corrocher; P. Votzakis; Ml. Pacor
Allergy | 2007
Giovanni Corrocher; G. Di Lorenzo; Pasquale Mansueto; Nicola Martinelli; Maria Esposito-Pellitteri; Giorgio Lombardo; R. Corrocher; Ml. Pacor
Allergy | 2007
Ml. Pacor; Pasquale Mansueto; Nicola Martinelli; Maria Esposito-Pellitteri; Vito Ditta; C. Lo Bianco; Maria Stefania Leto-Barone; R. Corrocher; Rini Gb; A. D'Alcamoa; G. Di Lorenzo